AB rating means it's therapeutically equivalent to brand name ... docs will rightly assume that GV should work just as well for the R-IT indication -
Physicians might make that assumption, but would it be "right"? You say it would; JT says it would not (or at least that the AB therapeutic equivalence rating applies only to severe hypertriglyceridemia). If JT is correct, Amarin should educate physicians to such effect, disabusing them of their assumption.
Are you so confident of your research that you are satisfied that your two, 0.5 gram capsules of Vascepa are the therapeutic equivalent of one, 1 gram capsule of Hikma's IPE for whatever indication you are taking it, such that you will take Hikma's product and believe it is having the same effect as did Amarin's product?